Meeting
2022 ASCO Quality Care Symposium
An overview of adverse event (AE) management for patients (pts) receiving abemaciclib.
Authors
Hope S. Rugo
Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo, Alexandra Vitko, Kelli Thoele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Toxicity Prevention, Assessment, and Management
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 239)
DOI
10.1200/JCO.2022.40.28_suppl.239
Abstract #
239
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.
First Author: Ezra Rosen
Poster
2023 ASCO Annual Meeting
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
First Author: Dejan Juric
First Author: Mafalda Oliveira
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu